title: Hirschsprung-associated enterocolitis: prevention and therapy.
abstract: Hirschsprung-associated enterocolitis remains the greatest cause of morbidity and mortality in children with Hirschsprung disease. This chapter details the various approaches used to treat and prevent this disease process. This includes prevention of complications, such as stricture formation, prophylaxis with rectal washouts, and identification of high-risk individuals. The chapter also details approaches to diagnose Hirschsprung-associated enterocolitis as well as to exclude other etiologies.
authors.affiliation: Division of Pediatric Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Philip.Frykman@cshs.org
authors.forename: Philip K
authors.initials: PK
authors.lastname: Frykman
authors.forename: Scott S
authors.initials: SS
authors.lastname: Short
mesh_terms: D001003:Anal Canal / Q000601:surgery; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003251:Constriction, Pathologic / Q000209:etiology / Q000517:prevention & control; D004106:Dilatation; D004760:Enterocolitis / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D004766:Enterostomy; D006627:Hirschsprung Disease / Q000150:complications* / Q000175:diagnosis / Q000601:surgery; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000209:etiology; D009465:Neuromuscular Agents / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control; D019936:Probiotics / Q000627:therapeutic use; D012008:Recurrence; D018570:Risk Assessment; D012307:Risk Factors; D007507:Therapeutic Irrigation
chemical_list: D000900:Anti-Bacterial Agents; D009465:Neuromuscular Agents; D001905:Botulinum Toxins